Name: LGNYZ Income Statement - Ligand Pharmaceuticals Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

LGNYZ - Ligand Pharmaceuticals Inc.

USD | NASDAQ | Healthcare

LGNYZ Income Statement - Ligand Pharmaceuticals Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	51.7	59.7	115.5	47.6	45.3	42.8	51.8	41.5	31.0	28.1	32.9	26.4	44.0	50.4	59.2	50.1

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenues
Revenues	274.5	268.1	167.1	131.3	196.2	241.5	163.6	120.3	251.5	141.1	109.0	71.9	64.5	49.0	31.4	30.0	23.5	38.9
Cost of Revenue	-	-	-	-	-	-	-	-	6.3	5.4	5.6	5.8	9.1	5.7	3.6	4.9	-	-
Gross Profit	-	-	-	-	-	-	-	-	245.1	135.7	103.4	66.1	55.4	43.2	27.8	25.1	-
Operating Expenses
Research & Development	33.2	81.2	21.4	24.5	36.1	32.1	40.5	55.9	27.9	26.9	21.2	11.0	9.7	9.3	10.8
Operating Income
Operating Income	94.6	41.0	(22.6)	11.9	3.0	103.9	37.5	807.1	163.7	68.1	43.9	27.3	19.6	14.9
Non-Operating
Interest Income	18.5	13.7	8.1	7.7	2.0	0.9	8.1	28.4	14.0	2.1	-	-	-	-	-	0.0
Tax & Net
Income Tax Expense	31.3	34.5	6.6	9.8	41.2	(4.1)	(5.3)	167.3	30.0	44.7	10.3	(192.1)	0.4	0.4	(1.2)
Per Share
EPS Basic	7.72	6.44	(0.22)	3.02	(1.98)	3.44	(0.18)	33.13	6.77	0.60	(0.08)	11.61	0.59	0.56	(0.03)	0.49
Supplementary Data
EBITDA	-	74.8	12.6	48.5	54.6	154.9	63.2	825.4	176.5	79.0	55.2	30.0	22.3	17.6	2.9	1.9

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	2.1	3.5	21.0	6.6	50.1	4.4	5.7	5.4	6.0	5.5	5.5	6.9	6.7	9.2	9.2	8.5	9.2	(18.7)	16.9	16.0	17.9	3.0	12.9	12.7	11.9	18.7	13.7	12.2	11.3	8.8	5.5	6.1	7.4	8.6	4.8	4.8	8.7	6.4	5.9	4.9
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	20.8	25.0	28.4	20.2	18.8	25.6	24.5	17.6	11.0	16.0	14.7	11.3	10.9	31.1	14.9	12.1	11.9
Depreciation & Amortization	8.2	-	-	-	8.8	-	-	-	8.8	-	-	-	9.5	-	-	-
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	-
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Operating Income
Operating Income	17.4	13.8	54.9	8.4	(36.2)	(9.6)	3.1	(19.1)	3.0	(3.4)	3.1	(2.0)	14.2	(20.1)	12.3	8.7	2.1	37.7	15.7	45.7	4.7	22.9	3.7	7.1	3.8	(10.2)	(5.2)	(4.1)	826.5	33.1	23.4	70.2	37.0	28.4	16.5	13.0	10.2	19.4	5.5	4.0

Tax & Net
Income Tax Expense	(10.9)	12.0	23.9	6.4	(7.7)	(8.1)	0.8	(13.5)	27.3	(1.1)	(1.9)	0.9	11.9	38.7	2.7	(3.9)	3.8	4.1	1.5	2.6	(12.3)	(0.1)	(4.9)	6.0	(6.3)	(0.8)	(4.6)	(3.6)	176.4	(14.3)	11.9	22.4	10.0	37.7	3.6	2.2	1.1	10.4	0.2	(3.9)
Net Income From Continuing Ops	(13.3)	44.8	117.3	4.8	(42.5)	(31.1)	(7.2)	(51.9)	86.1	18.2	(10.3)	2.3	43.6	(14.5)	9.6	12.6	(12.9)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(13.3)	44.8	117.3	4.8	(42.5)	(31.1)	(7.2)	(51.9)	86.1	18.2	(10.3)	2.3	41.9	(17.5)	0.4	(0.9)	(15.4)
Net Income Attributable To Parent	(13.3)	44.8	117.3	4.8	(42.5)	(31.1)	(7.2)	(51.9)	86.1	18.2	(10.3)	2.3	41.9	(17.5)	0.4	(0.9)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(13.3)	44.8	117.3	4.8	(42.5)	(31.1)	(7.2)	(51.9)	86.1	18.2	(10.3)	2.3	41.9	(17.5)	0.4

Per Share
EPS Basic	(0.67)	-	5.99	0.25	(2.21)	-	(0.39)	(2.88)	4.86	-	(0.59)	0.13	2.46	-	0.02	(0.05)	(0.91)	-	0.82	1.84	1.10	-	(0.42)	1.38	(1.46)	-	(0.81)	(0.74)	32.59	-	3.19	3.45	2.13	-	0.40	0.29	0.24	-	0.05	(0.30)
EPS Diluted	(0.67)	-	5.68	0.24	(2.21)	-	(0.39)	(2.88)	4.75	-	(0.59)	0.13	2.33	-	0.02	(0.05)	(0.91)	-
Shares Basic	19.9	-	19.6	19.3	19.2	-	18.4	18.0	17.7	-	17.4	17.3	17.1	-	16.9	16.9	16.8	-
Shares Diluted	19.9	-	20.6	19.9	19.2	-	18.4	18.0	18.1	-	17.4	17.7	18.0	-	17.1	17.1	16.8	-

Supplementary Data
EBITDA	25.6	-	-	-	(27.4)	-	-	-	11.8	-	-	-	23.7	-	-	-	15.8	-	-	-	17.3	-	-	-	7.2	-	-	-	830.4	-	-	-	40.0	-	-	-	13.2	-	-	4.1
EBIT	17.4	13.8	54.9	8.4	(36.2)	(9.6)	3.1	(19.1)	3.0	(3.4)	3.1	(2.0)	14.2	(20.1)	12.3	8.7	2.1	37.7	15.7

Non-Operating
Interest Income	6.7	6.4	3.9	1.6	1.8	1.9	1.3	2.8	2.0	1.7	2.3	2.3	1.4	1.0	0.6	0.3	0.1	0.2	0.2	0.2	0.3	0.4	1.0	2.0	4.7	5.8	7.4	9.3	5.9	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	1.7	1.8	0.9	1.2	0.9	0.9	0.7	1.3	0.1	0.1	0.0	0.3	0.2	0.2	0.3	0.4	0.8	4.5
Income From Equity Investments	-	-	-	-	0.0	-	-	-	(2.4)	-	-	-	0.0	-	-	-
Other Non-Operating Income	(41.6)	42.9	86.2	2.8	(14.0)	(29.6)	(9.5)	(46.3)	110.5	20.5	(15.2)	5.2	41.3	44.2	0.0	(0.0)	(11.3)
Pre-Tax Income	(24.3)	56.8	141.1	11.2	(50.2)	(39.2)	(6.3)	(65.4)	113.4	17.1	(12.1)	3.2	55.5	24.1	12.4	8.7